Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Pediatric Oncology
•
Lymphoma
•
Non-Hodgkin Lymphoma
•
Hematology
•
T-Cell Lymphoma
How would you treat a pediatric or adolescent patient with peripheral T-cell lymphoma NOS?
Related Questions
What are your practical considerations for incorporating bispecific antibody therapy into treatment of relapsed DLBCL?
Are there biomarkers or other factors to help predict which patients with MCL are most likely to benefit, or not, from pirtobrutinib following a prior covalent BTKi?
How would you manage a young, HIV-negative patient with good performance status with primary refractory Burkitt Lymphoma involving the CNS and systemic disease?
How are you deciding between available third line therapies for post-transplant relapsed DLBCL?
How would you approach treatment for a R/R mantle cell lymphoma patient with a history of autoimmune hepatitis who has progressed on both a covalent and non-covalent BTKi?
For pediatric patients with localized diffuse large B-cell lymphoma being treated per COG ANHL 1131 in group B, do you feel it is necessary to complete all lumbar punctures with IT therapy?
Will you recommend pirtobrutinib following a prior covalent BTKi in patients with cardiac comorbidities?
Are you including Bortezomib as standard of care in the upfront treatment of T lymphoblastic-lymphoma?
What is the preferred treatment for a patient with an EBV+ monomorphic PTLD (DLBCL) not currently on immunosuppressive therapy?
Following the BRUIN data in mantle cell lymphoma, will you routinely treat with pirtobrutinib following a covalent BTKi?